Yifan Pharmaceutical Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Yifan Pharmaceutical Co., Ltd. carries a market capitalization of 11.97B, placing it among publicly traded companies globally. Its enterprise value stands at 17.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.97B |
| Enterprise Value | 17.20B |
Share Statistics
Yifan Pharmaceutical Co., Ltd. currently has 1.22B shares outstanding.
| Shares Outstanding | 1.22B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Yifan Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 36.21. The price-to-sales ratio is 3.06, and the price-to-book ratio stands at 2.78.
| PE Ratio | 36.21 |
| PS Ratio | 3.06 |
| PB Ratio | 2.78 |
| P/TBV Ratio | 4.59 |
| P/FCF Ratio | 25.49 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Yifan Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 27.61 and an EV/FCF ratio of 25.47. The EV/Sales ratio of 3.33 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 27.61 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.33 |
| EV / EBITDA | 27.61 |
| EV / EBIT | 27.61 |
| EV / FCF | 25.47 |
Financial Position
Yifan Pharmaceutical Co., Ltd. maintains a current ratio of 1.31, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 26.52, indicating elevated leverage, while an interest coverage ratio of 10.13 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.31 |
| Quick Ratio | 0.26 |
| Debt / Equity | 26.52 |
| Debt / EBITDA | 3.69 |
| Interest Coverage | 10.13 |
Financial Efficiency
Yifan Pharmaceutical Co., Ltd. posts a return on equity of 7.80 and a return on invested capital of 5.27.
| Return on Equity (ROE) | 7.80 |
| Return on Assets (ROA) | 3.52 |
| Return on Invested Capital (ROIC) | 5.27 |
| Return on Capital Employed (ROCE) | 6.87 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.36 |
Taxes
Over the trailing twelve months, Yifan Pharmaceutical Co., Ltd. has paid 44.00M in income taxes, reflecting an effective tax rate of 10.01.
| Income Tax | 44.00M |
| Effective Tax Rate | 10.01 |
Stock Price Statistics
Yifan Pharmaceutical Co., Ltd.'s stock has declined approximately -28.38428% over the past 52 weeks. The 50-day moving average sits at 10.38, while the 200-day moving average is 12.16.
| Beta (5Y) | N/A |
| 52-Week Price Change | -28.38428% |
| 50-Day Moving Average | 10.38 |
| 200-Day Moving Average | 12.16 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Yifan Pharmaceutical Co., Ltd. generated 5.16B in revenue and converted that into 436.39M in net income, yielding earnings per share of 0.32. EBITDA reached 622.90M, while operating income came in at 622.90M.
| Revenue | 5.16B |
| Gross Profit | 2.47B |
| Operating Income | 622.90M |
| Pretax Income | 439.33M |
| Net Income | 436.39M |
| EBITDA | 622.90M |
| EBIT | 622.90M |
| Earnings Per Share (EPS) | 0.32 |
Balance Sheet
Yifan Pharmaceutical Co., Ltd. holds 785.91M in cash and equivalents against 2.30B in total debt, resulting in a net debt position of 1.08B. Total book value stands at 5.69B, with working capital of 935.03M providing operational flexibility.
| Cash & Cash Equivalents | 785.91M |
| Total Debt | 2.30B |
| Net Debt | 1.08B |
| Equity (Book Value) | 5.69B |
| Book Value Per Share | 4.67 |
| Working Capital | 935.03M |
Cash Flow
After subtracting -619.98M in capital expenditures, free cash flow totaled -619.98M - equivalent to -0.51 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -619.98M |
| Free Cash Flow | -619.98M |
| FCF Per Share | -0.51 |
Margins
Yifan Pharmaceutical Co., Ltd. operates with a gross margin of 47.83, reflecting its pricing power and cost economics. The operating margin of 12.06 and net profit margin of 8.45 provide insight into operational efficiency.
| Gross Margin | 47.83 |
| Operating Margin | 12.06 |
| Pretax Margin | 8.51 |
| Profit Margin | 8.45 |
| EBITDA Margin | 12.06 |
Dividends & Yields
The company's payout ratio of 87.58 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.26 |
| Dividend Yield | N/A |
| Payout Ratio | 87.58 |
| Shareholder Yield | 1.53 |
| FCF Yield | 3.92 |
Stock Splits
Yifan Pharmaceutical Co., Ltd.'s most recent stock split took place on May 16, 2016 with a 2:5 split ratio.
| Last Split Date | 5/16/2016 |
| Split Ratio | 2:5 |
Scores
Yifan Pharmaceutical Co., Ltd. posts an Altman Z-Score of 4.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.35 |